SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents

Gravett, A; Dennis, J; Dalgleish, A; Copier, J; Liu, W (2020) The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents. Oncology Letters, 20 (6). p. 1. ISSN 1792-1074 https://doi.org/10.3892/ol.2020.12184
SGUL Authors: Liu, Wai Man

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Determining the expression of genes in response to different classes of chemotherapeutic drugs may allow for a better understanding as to which may be used effectively in combination. In the present study, the human colorectal cancer cell line HCT116 was cultured with equi‑active concentrations of a series of anti‑cancer agents. Gene expression profiles were then measured by whole‑genome microarray. Although each drug induced a unique signature of gene expression in tumour cells, there were marked similarities between certain drugs, even in those from different classes. For example, the antimalarial agent artesunate and the platinum‑containing alkylating agent, oxaliplatin, produced a very similar mRNA expression pattern in HCT116 cells with ~14,000 genes being affected by the two drugs in the same way. Furthermore, the overall correlation of gene responses between two agents could predict whether their use in combination would lead to a greater or lesser effect on cell number, determined experimentally, than predicted by single agent experiments. The results indicated that even when working through different mechanisms, combining drugs that initiate a similar transcriptional response may constitute the best option for determining drug‑combination strategies for the treatment of cancer.

Item Type: Article
Additional Information: © Gravett et al. This is an open access article distributed under the terms of Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Oncology Letters
ISSN: 1792-1074
Dates:
DateEvent
1 October 2020Published
10 July 2020Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDInstitute for Cancer Vaccines and ImmunotherapyUNSPECIFIED
URI: https://openaccess.sgul.ac.uk/id/eprint/112529
Publisher's version: https://doi.org/10.3892/ol.2020.12184

Actions (login required)

Edit Item Edit Item